Aardvark Therapeutics (AARD) Non-Current Assets (2024 - 2026)
Aardvark Therapeutics (AARD) posted Non-Current Assets of $5.0 million for Q1 2026, down 5.38% sequentially from $5.3 million in Q4 2025, and up 102.75% YoY from $2.5 million in Q1 2025.
Aardvark Therapeutics (AARD) Non-Current Assets (2024 - 2026) Analysis & Trends
Aardvark Therapeutics has reported Non-Current Assets for 3 years, with the latest figure at $5.0 million in Q1 2026.
- Quarterly Non-Current Assets rose 102.75% year-over-year to $5.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $17.0 million (changed N/A YoY) and the FY2025 annual result came in at $5.3 million, up 57.12% from the prior year.
- Non-Current Assets retreated to $5.0 million in Q1 2026 per AARD's latest filing, from $5.3 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $5.3 million in Q4 2025 and troughed at $2.5 million in Q1 2025.
- A 3-year average of $3.8 million and a median of $3.7 million in 2024 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2025 and 2026: Non-Current Assets surged 57.12% in 2025, then surged 102.75% in 2026.
- Over 3 years, Non-Current Assets stood at $3.4 million in 2024, then soared by 57.12% to $5.3 million in 2025, then retreated by 5.38% to $5.0 million in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $5.0 million, $5.3 million, and $4.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 938.60 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 468.65 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 18.06 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 6.80 Bn |
| 10 | Aardvark Therapeutics | 127.36 Mn | 53.44 Mn | - | 799,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 799,000.00 |
| Mar 31, 2026 | 5.01 Mn |
| Dec 31, 2025 | 5.30 Mn |
| Sep 30, 2025 | 4.02 Mn |
| Jun 30, 2025 | 2.71 Mn |
| Mar 31, 2025 | 2.47 Mn |
| Dec 31, 2024 | 3.37 Mn |